What is Sidoti’s Forecast for HBIO Q3 Earnings?

Harvard Bioscience, Inc. (NASDAQ:HBIO) – Equities research analysts at Sidoti issued their Q3 2026 earnings estimates for shares of Harvard Bioscience in a research note issued on Saturday, October 31st. Sidoti analyst J. Sidoti forecasts that the medical instruments supplier will post earnings of ($0.65) per share for the quarter. Sidoti also issued estimates for Harvard Bioscience’s Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($1.15) EPS, Q1 2028 earnings at $0.06 EPS, Q2 2028 earnings at $0.06 EPS, Q3 2028 earnings at $0.05 EPS and FY2028 earnings at $0.43 EPS.

HBIO has been the subject of a number of other research reports. Weiss Ratings cut Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. Benchmark boosted their price objective on Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Harvard Bioscience Stock Up 0.8%

Shares of HBIO stock opened at $8.67 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 0.98 and a debt-to-equity ratio of 4.94. The stock has a 50 day moving average of $8.17 and a 200 day moving average of $6.46. Harvard Bioscience has a twelve month low of $4.00 and a twelve month high of $9.10.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Harvard Bioscience had a negative return on equity of 33.13% and a negative net margin of 11.86%. The business had revenue of $22.73 million for the quarter, compared to analyst estimates of $21.45 million.

Institutional Trading of Harvard Bioscience

A hedge fund recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC bought a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned 0.29% of Harvard Bioscience as of its most recent SEC filing. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience News Roundup

Here are the key news stories impacting Harvard Bioscience this week:

• Positive Sentiment: Sidoti forecasts Harvard Bioscience will earn $0.43 per share in fiscal 2028, with quarterly profits of $0.05–$0.06 beginning in Q1 2028. That projected turnaround could support investor optimism, though it remains a forecast. MarketBeat coverage
• Neutral Sentiment: CEO John Duke and CFO Mark Frost will participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11. The announcement provides an opportunity for investor engagement but includes no new financial or operating details. Forum announcement
• Negative Sentiment: Sidoti expects continued losses in the nearer term, forecasting a $2.44-per-share loss for 2026 and a $1.15-per-share loss for 2027. Those estimates may temper the positive longer-term outlook. MarketBeat coverage

About Harvard Bioscience

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.